Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20831347 | 0.85 | MEN1 (0.56) | GAAALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL20530133 | 0.81 | NPC1 (0.52) | LMNAKMT2AMEN1MAPTPOLB | |
| SCHEMBL12780080 | 0.78 | CYP1A2 (0.61) | GAAALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL165300 | 0.78 | CYP1A2 (0.61) | GAAALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL165299 | 0.78 | CYP1A2 (0.61) | GAAALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL28353958 | 0.77 | MEN1 (0.46) | ALDH1A1KMT2AMEN1POLBSMN1; SMN2 | |
| SCHEMBL20024696 | 0.76 | AHR (0.56) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL8339774 | 0.75 | MAPT (0.52) | KDM4EMAPT | |
| SCHEMBL16609588 | 0.75 | KDM4E (0.68) | GAAALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL25583746 | 0.75 | HDAC2 (0.60) | GAAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3606921-B1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | INVENTIVA (FR) | 2022-06-01 | — | — | EP | disclosed |
| US-20200115353-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA | INVENTIVA (FR) | 2020-04-16 | — | — | US | disclosed |
| EP-3606921-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | Inventiva (FR) | 2020-02-12 | — | — | EP | disclosed |
| WO-2018185266-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | INVENTIVA (FR) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115353-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA | YAP1, TEAD2, TEAD1 | GAA 4855/4885ALDH1A1 3397/4885KDM4E 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.